In announcement no. 15-09 of 7 May 2009, NeuroSearch announced the launch of a
share purchase programme under which the company will buy own shares for an
amount of up to DKK 50 million during 2009. 

The programme is structured according to European Commission Regulation No
2273/2003 of 22 December 2003, also referred to as the “Safe Harbour” rules,
for the purchase of own shares. 

In the past week, since the issue of status announcement no. 41-09 of 31 August
2009, the following transactions have been made under NeuroSearch's share
purchase programme: 

Accumulated share purchase / Number of shares / Average price (DKK) /
Transaction value (DKK) 

31 Aug 2009	3,182	125.46	399,213
1 Sept 2009	1,500	125.53	188,295
2 Sept 2009	-	-	-
3 Sept 2009	-	-	-
4 Sept 2009	500	124.00	62,000
Total 	        5,182	125.24	649,508


With the purchased amount of shares as stated above, NeuroSearch now holds a
total of 248,469 treasury shares of DKK 20 nominal value each, corresponding to
1.44% of the total number of 17,237,830 issued shares in NeuroSearch A/S. 

An amount of DKK 22,510,369 remains to be used under the share purchase
programme. Based on the closing price for NeuroSearch shares on NASDAQ OMX
Copenhagen on Friday 4 September 2009, this corresponds to a maximum of 177,947
additional NeuroSearch shares to be bought under the programme. 


Flemming Pedersen
CEO


Contact persons:

Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103 


About NeuroSearch  
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline (GSK), and license collaboration with Abbott. The drug pipeline
comprises seven clinical (Phase I-III) development programmes: Huntexil™
(Pridopidine) for Huntington's disease (Phase III), tesofensine for obesity
(Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott,
ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias in
Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase
I) and NSD-721 for social anxiety disorder (Phase I). In addition, NeuroSearch
has a broad portfolio of preclinical drug candidates and holds equity interests
in several biotech companies.